# The Questions People Actually Type > Questions — Research Peptide Fundamentals | The Peptide Train — Direct answers on Research Peptide Fundamentals research peptides — what BPC-157, CJC-1295, ipamorelin and tirzepatide are, what the trials found, and what the published record says about combining any of them. **QUESTIONS** Answered from the numbered sources on this desk's reference list, including the ones where the honest answer is that nobody has looked. ## What does BPC-157 do in the body? In animal models it acts as a cytoprotective and repair signal, and the effect most consistently linked to it is angiogenesis — the growth of new blood vessels into damaged tissue. The best-characterised route runs through the VEGFR2 receptor, which BPC157 up-regulates and helps internalise, activating the VEGFR2-Akt-eNOS pathway; vessel density rose and blood-flow recovery in ischaemic muscle accelerated in that work [4]. Additional routes described in the literature include modulation of serotonergic and dopaminergic systems along the brain-gut axis [7]. In humans, the published record does not extend to demonstrating any of this [2]. ## Is BPC-157 a growth hormone? No. BPC-157 is a fifteen-amino-acid peptide derived from a protein found in gastric juice, and it is not a hormone, not a growth hormone, and not a growth-hormone secretagogue. It does not act at the pituitary. The confusion is understandable, because BPC-157 is frequently listed alongside compounds that do act on the growth-hormone axis, such as CJC-1295 and ipamorelin. One indirect connection exists in the literature — in cultured tendon cells BPC-157 increased growth-hormone-receptor signalling — but sensitising a receptor in tissue is a different thing from being, or releasing, the hormone itself. ## Does BPC-157 damage the liver? Nothing in the published record shows liver damage, and nothing in it is large enough to rule the question out either. The one relevant human dataset is an intravenous safety pilot in two healthy adults at up to 20 mg, which reported no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers [1]. Two participants is not a safety database. A 2025 review counts three small human pilot studies in total and describes rigorous large-scale trials as lacking [2], which means long-term organ safety in people is genuinely uncharacterised rather than reassuringly negative. ## What is CJC-1295? A synthetic analogue of growth-hormone-releasing hormone, built on the first 29 residues of human growth-hormone-releasing factor with four amino-acid substitutions that protect it from enzymatic breakdown. The long-acting DAC version carries a linker that binds covalently to albumin in the blood, extending its plasma half-life toward albumin's own; the short-acting no-DAC version, usually sold as Modified GRF 1-29, has the substitutions but no albumin arm and behaves very differently. It has never been approved for human use anywhere, is handled as a research chemical, and is prohibited in sport at all times [8]. ## What does CJC-1295 do? It binds the growth-hormone-releasing hormone receptor on pituitary somatotrophs, activating the Gs-cyclic-AMP-PKA pathway that drives synthesis and pulsatile release of growth hormone, which in turn raises IGF-1 in the liver. In healthy adults, single subcutaneous doses of 30 or 60 micrograms per kilogram raised mean plasma growth hormone two- to ten-fold for six days or more and IGF-1 1.5- to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days [11]. Notably, pulsatile secretion was not flattened by the sustained stimulation [12]. ## Is CJC-1295 safe? There is not enough human data to answer that, which is itself the answer. The published human record is a small number of early pharmacology studies, with no large or long-term trial in healthy adults [11]. The documented concerns are mechanism-based: sustained IGF-1 elevation against a population-level association between higher IGF-1 and modestly increased risk of certain cancers; fluid retention and nerve-compression effects from growth-hormone-driven sodium and water retention; reduced insulin sensitivity, since growth hormone is glucose-sparing; and immunogenicity, cited in 2024 FDA compounding-committee materials [8]. Its original long-acting development programme was discontinued and never reached approval. ## How much CJC-1295 should I take? This desk does not answer dosing questions, and the literature is not in a position to answer this one either. CJC-1295 is not approved for human use anywhere and has no established human dose. What exists is early pharmacology: single subcutaneous doses of 30 or 60 micrograms per kilogram in healthy adults produced dose-dependent growth-hormone and IGF-1 elevation lasting days [11], and doses of 60 or 90 micrograms per kilogram were used in a second study of pulsatility [12]. Those are descriptions of what investigators administered under supervision in a research setting. They are not a recommendation, and they are not a schedule. ## What is ipamorelin? A synthetic pentapeptide that selectively activates the ghrelin receptor, formally the growth hormone secretagogue receptor 1a, on pituitary somatotrophs — producing a pulse of growth hormone. It was derived from the earlier compound GHRP-1 and also appears under the code NNC 26-0161. Its defining pharmacological feature is selectivity: unlike the older growth-hormone-releasing peptides GHRP-6 and GHRP-2, it does not meaningfully raise ACTH, cortisol or prolactin even well above the exposure needed to release growth hormone. It has never been approved as a drug for any indication and is prohibited in sport at all times. ## What are the risks of ipamorelin? The largest one is how little is known. The controlled human dataset is a single phase 2 trial over a seven-day window [15] plus an acute pharmacokinetic study [16], with no phase 3 trial and no long-term safety database. Subcutaneous self-administration, the dominant route in research use, has no published human characterisation at all. Beyond that, the documented concerns are mechanistic and class-level: raising growth-hormone pulse amplitude raises IGF-1, a known mitogen [17]; agonists at this receptor stimulate appetite; the compound has a direct insulinotropic action on pancreatic tissue; and a 28-day rodent study of a related agonist at the same receptor found dose-dependent myocardial degeneration [14]. ## What is tirzepatide? A linear 39-amino-acid synthetic peptide based on the native GIP sequence, carrying a C20 fatty diacid that binds albumin and extends its half-life enough to allow once-weekly dosing. It is the first approved dual incretin agonist, engaging both the GIP receptor and the GLP-1 receptor with a single molecule [19]. It is also the one compound on this site that is an approved prescription medicine rather than a research chemical: a peer-reviewed clinical-reference chapter records approval in May 2022 for type 2 diabetes, and notes that it is not approved for type 1 diabetes [19]. ## How does tirzepatide work? By imitating two gut hormones at once. Activating both the GIP and the GLP-1 receptor enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake [19]. *Glucose-dependent* matters: insulin release is stimulated in proportion to how much glucose is present, which is why the compound alone carries a low risk of driving blood sugar too low, and why that risk rises when it is combined with insulin or a sulfonylurea. Engaging two receptors rather than one produced larger effects in trials than single-receptor agonism, which is the premise the head-to-head studies tested [18][22]. ## What is tirzepatide used for? The clinical-reference chapter on this desk's source list records its FDA approval in May 2022 for type 2 diabetes and treats weight-loss use as off-label at the time of that writing, while noting it is not approved for type 1 diabetes [19]. Approvals in this category have moved since, and the current prescribing information is the authority on indications rather than any summary. The trial programme has measured it on two main endpoints: body weight in adults with obesity [18][21] and glycated haemoglobin in adults with type 2 diabetes [22]. It is prescription-only in the United States. --- The Peptide Train follows four habitually bundled peptides back through their own published records and reports the exact point where the reporting has to stop — it sells nothing, prescribes nothing, and endorses no pairing to anyone.